Focal.One offers state-of-the-art imaging to localize tumors with the use of MRI combined with real-time ultrasound. The HIFU treatment provides precision targeting because it is focused on identified cancer areas only. Contrast-enhanced ultrasound imaging provides immediate feedback on treatment efficacy.
EDAP said that it expects to file for CE Mark approval for Focal.One in the second quarter of 2013 and pursue commercial distribution in Europe thereafter.
EDAP promotes ultrasound endorsements, June 12, 2012
EDAP reports prostate ultrasound advances in Bordeaux, June 5, 2012
EDAP products registered in France, December 7, 2010
EDAP to push European marketing efforts, August 4, 2006